DRUG
Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment
Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.
India may open doors to multinational pharma firms for first-in-human Phase I trials
India is considering modifications to its pharmaceutical regulatory framework to attract multinational companies for clinical trials. Discussions have commenced regarding allowing these companies to conduct Phase I trials in India. Authorities aim to enhance India's appeal for global drug innovation and development. Strengthening manufacturing compliance over the last two years has also been part of the plan.
Dario Amodei says AI could make cancer, Alzheimer’s ‘relics of the past’ in less than a decade as Anthropic expands AI-driven drug discovery push
Anthropic is collaborating with several pharmaceutical companies to utilize AI in drug development processes. These partnerships aim to improve the efficiency of drug discovery, addressing complex challenges in medical research. Notable projects include redesigning therapeutic molecules and accelerating antibody designs for various diseases. Anthropic has also initiated its own research on rare childhood muscular dystrophies, targeting potential clinical trials by late 2028.
USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'
The facility belongs to Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma. The US Food and Drug Administration (USFDA) conducted the inspection at the Seymour facility from August 17-21, 2026, Aurobindo Pharma said in a regulatory filing.
Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA
Following an inspection from September 7 to September 15, 2026, the US FDA granted Apitoria Pharma, a subsidiary of Aurobindo Pharma, a Voluntary Action Indicated classification. This classification indicates that although objectionable conditions were found in the Telangana manufacturing facility, the absence of immediate regulatory action allows the company to address the issues through voluntary corrective measures.
GLP-1 drugs for weight loss Ozempic, Wegovy linked to vision loss: What is NAION, who is at risk and what symptoms should users watch for?
Side effects of weight loss drugs: The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label about a possible link to permanent vision loss, the US Food and Drug Administration has said. Older age people, those suffering with diabetes, high blood pressure are at a higher risk. NAION typically causes sudden, painless vision loss, often affecting one eye.
- Go To Page 1
US FDA adds rare vision-loss warning to popular GLP-1 drugs
The US FDA will add a warning about a rare eye condition that can cause permanent vision loss to the labels of all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound. The condition was found in around 6 per 100,000 patients taking the drugs for at least a year.
India, US vow to jointly act against emerging drug threats
India and the US have agreed to strengthen cooperation against emerging narcotics threats, including illicit drug trafficking and the diversion of synthetic drugs and chemical precursors. At a bilateral meeting in New Delhi, both sides discussed intelligence sharing, coordinated enforcement, precursor control, pharmaceutical supply chains and measures to reduce drug demand.
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
Over 1,300 anti-cancer drugs to get cheaper
India's National Pharmaceutical Pricing Authority is set to cap trade margins on anti-cancer drugs starting November 2026. The initiative aims to save around ₹2,500 crore annually for cancer patients. The list includes 1,366 drug brands, with substantial price reductions for several high-cost medications. However, some patented drugs will maintain their prices despite the changes. Patients and medical institutions are directed to display revised prices prominently.
Home Minister Amit Shah sets December 2028 drug-free Gujarat target, a year ahead of national deadline
Union Home Minister Amit Shah on Monday set December 31, 2028, as the deadline to make Gujarat drug-free, a year ahead of India’s December 31, 2029, target. Addressing a gathering in Ahmedabad, he urged citizens to report drug abuse and drug sales to authorities, stressing that government efforts alone cannot eliminate narcotics.
Cancer drug prices revised from today; patients may save Rs 3,540 crore annually
The government has revised the prices of 1,364 anti-cancer medicine formulations effective from November 9. This decision aims to limit trade margins and reduce consumer costs for cancer drugs. According to official reports, this measure is expected to save consumers Rs 3,540.38 crore each year.
Morepen Laboratories launches Desloratadine (Rx) generic drug product in US market
Morepen Laboratories has launched its prescription generic product Desloratadine in the United States market. This launch is managed through the company's subsidiary, Morpen Bio. Inc. The product will be available in 100-count and 500-count packs to consumers. Additionally, Morepen has submitted an Abbreviated New Drug Application for Sitagliptin Phosphate Tablets to the US FDA. The submission is currently undergoing regulatory review, which is an important step for their expansion.
Cancer drug prices to fall by up to 96% from November 9; consumers set to save Rs 3,502 crore annually
Starting November 9, consumers in India will benefit from significantly reduced prices on 137 anti-cancer drugs. The government has capped trade margins on these medications, leading to an estimated annual savings of Rs 3,502.31 crore for consumers. Price reductions have been reported across 1,225 formulations, with some reductions exceeding 50 percent.
Scientists gave mice an existing asthma drug before exposing them to peanut extract; 95% were protected from severe allergic reactions in the experiment
Researchers at Northwestern University found that the asthma drug Zileuton reduces allergic reactions in mice fed peanut extract. The study indicates that Zileuton could block the inflammation that leads to anaphylaxis. While it works in mice, clinical trials in humans are just beginning. This research highlights a new biological pathway related to food allergies and the immune response.
Russell Brand, a rape and sexual assault convict, has been a drug and alcohol addict in the past; here’s what we know about his notorious past
Russell Brand faced conviction for the rape of one woman and for sexually assaulting three others in a recent court ruling. While he was acquitted on two other rape counts and an attempted indecent assault charge, he has been remanded in custody without bail due to concerns of him fleeing the jurisdiction.
FDA flags persistent data-integrity lapses, insanitary conditions at Indian drug facilities
The US FDA continues to identify serious data integrity issues in Indian pharmaceutical manufacturing facilities. During inspections, inspectors found discarded documents related to key manufacturing processes, highlighting compliance concerns. To ensure safe medicines, drugmakers are urged to scrutinize their supply chains and monitor suppliers effectively. Additionally, human errors contributed significantly to production incidents, affecting operations and batch release timelines.
I was offered coke at 11: Dafne Keen reveals the 'peer pressure' to do drugs she faced at Hollywood parties as a child actor
Dafne Keen, best known for playing Laura/X-23 alongside Hugh Jackman in Logan, has revealed that she was offered cocaine at Hollywood wrap parties when she was just 11, 12 and 13. Speaking on the Inside of You podcast, the 21-year-old actress explained how witnessing drug and alcohol culture as a child made her avoid substances. She also recalled lying about being high as a teenager to escape peer pressure to drink.
Centre proposes 10 new entry points for drug imports into India, Noida airport included
The Centre has proposed expanding India's authorised import network for pharmaceuticals and medical devices by adding ten new locations. These include Noida International Airport and several inland container depots across industrial hubs in India. This expansion aims to simplify the import process and reduce transportation costs for companies. The health ministry has invited public feedback on the draft amendment to Drugs Rules, 1945.
Govt plans instant ban on manufacturing of drugs failing key quality tests
Pharma companies could have their drug licenses suspended immediately if quality tests indicate failure. The health ministry's proposed changes aim to protect public health by enforcing swift action on substandard medications. Regulators would take action upon receiving a government analyst's report declaring a drug not of standard quality. Manufacturers would need to perform a root cause analysis and implement corrective actions to lift the suspension.
Punjab: Rahul Gandhi targets CM Bhagwant Mann over 'Nasha', says AAP govt run from Delhi
Rahul Gandhi launched the Congress campaign in Sangrur, criticizing Chief Minister Bhagwant Mann's handling of addiction issues. He claimed that Mann's alleged alcohol use undermines efforts to combat substance abuse in Punjab. Gandhi accused AAP leader Arvind Kejriwal of controlling the Punjab government from Delhi, asserting that the state needs local leadership. He also challenged Union Home Minister Amit Shah's promises regarding drug eradication by 2029.
'Mann smelled of alcohol in Parliament by 11 am', Rahul Gandhi launches all-out attack on AAP at Sangrur rally
Rahul Gandhi launched a campaign rally in Sangrur where he criticised Chief Minister Bhagwant Mann and Aam Aadmi Party for failing to address drug issues. He recalled earlier discussions about Punjab's drug crisis and asserted that AAP made promises but has not delivered results. Gandhi also expressed his disdain for BJP's tactics in Parliament, challenging Prime Minister Modi to debate openly on national issues.
‘Punjab’s remote control is in Delhi’: Rahul Gandhi attacks AAP, Bhagwant Mann over drugs; challenges PM for an open debate
Rahul Gandhi held an 'Insaaf Rally' in Sangrur, where he criticized the Aam Aadmi Party's governance in Punjab. He questioned Chief Minister Bhagwant Mann's effectiveness in combating drug abuse, emphasizing that Punjab needs a state-focused government. Gandhi recalled his concern for slain singer Sidhu Moose Wala, highlighting the threats faced by talented individuals in the state.
NPPA updates list of reduced MRP of 1,085 anti-cancer drugs
The National Pharmaceutical Pricing Authority updated the maximum retail price for 1,085 anti-cancer medicines. This revision follows a previous decrease of prices for 543 anti-cancer drugs announced on October 28. The updated list contains prices based on information submitted by pharmaceutical companies up to November 3. The NPPA will continuously update this list as more manufacturers submit revised prices.
Wockhardt seeks 14-year data shield for India-made drugs
Mumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for difficult-to-treat infections. In May this year, the company secured approvals from Indian and US drug regulators for a breakthrough drug, Zaynich (cefepime + zidebactam), to treat complicated urinary tract infection, including acute pyelonephritis or severe kidney infections. Wockhardt has showcased six drugs to treat antimicrobial resistance (AMR).
Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back
The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.
High Court restrains NPPA from action against AstraZeneca
The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.
UC innovations make TIME’s Best Inventions of 2026: How a pancreatic cancer drug and smarter wheelchair are changing lives?
From a pancreatic cancer drug that targets KRAS mutations to a smarter power wheelchair, University of California research is reaching beyond laboratories. Daraxonrasib, developed from discoveries at UCSF, received FDA approval in August. Meanwhile, UC Berkeley alumnus Tony Hong’s Strutt ev¹ uses sensors and voice controls to make everyday mobility easier.
Load More
